BALAXI PHARMACEUTICALS Q4 FY26 Results Preview: Revenue, PAT & EBITDA Growth Expectations

BALAXI PHARMACEUTICALS Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. BALAXI PHARMACEUTICALS was listed on the National Stock Exchange (NSE) on 30-Nov-2015. BALAXI PHARMACEUTICALS share has its face value of 2 per share, and its NSE symbol is BALAXI. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.

BALAXI PHARMACEUTICALS Q4 Results 2026 Preview

• BALAXI PHARMACEUTICALS Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 8% YoY increase compared to the same quarter last year.
• Profit After Tax, or PAT, is projected to rise 18% YoY.
• EBITDA to rise 7%.
• BALAXI PHARMACEUTICALS is expected to show Moderate Growth Expected in its revenue. 

Click and Sign Up to Get Live Updates on Q4 Results

BALAXI PHARMACEUTICALS Share Performance

• Over the past six months, BALAXI PHARMACEUTICALS share price has positive by 37% to 19.1.
• Moreover, over the past year, the stock has positive by 43%
• Despite this weak short-term performance, BALAXI PHARMACEUTICALS stock has delivered a financially sound 59% return over the past 5 years.
• As of today, 13-03-2026, the BALAXI PHARMACEUTICALS share price is trading at 19.1 per share.

Key Factors to Watch for BALAXI PHARMACEUTICALS Q4 Results FY26

• Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
• Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
• Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
• Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
• Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

About BALAXI PHARMACEUTICALS

BALAXI PHARMACEUTICALS operates in the healthcare segment and focuses on expanding its product portfolio, improving operational efficiency, and strengthening distribution across domestic and export markets. The company continues to focus on growth through innovation, capacity expansion, and improving margins while maintaining a strong presence in its core business segments.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts

BALAXI PHARMACEUTICALS is gear up to announce its Q4 FY26 results. Analysts expect 8% revenue growth, a 18% rise in PAT, and a 7% rise in EBITDA. BALAXI PHARMACEUTICALS focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on BALAXI PHARMACEUTICALS Q4 results FY26. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Advent Hotels International Q4 FY26 Results Preview

Advani Hotels Q4 FY26 Results Preview & Outlook

Advance Agrolife Q4 FY26 Results Preview & Outlook

Advait Energy Transitions Q4 FY26 Results Preview

Adroit Infotech Q4 FY26 Results Preview & Outlook

Archidply Decor Q4 FY26 Results Preview & Outlook